Literature DB >> 20804487

Age-related properties of the tumour vasculature in renal cell carcinoma.

Brian Meehan1, Sree Appu, Brad St Croix, Krystyna Rak-Poznanska, Laurence Klotz, Janusz Rak.   

Abstract

OBJECTIVE: To assess whether ageing processes influence angiogenesis in renal cell carcinoma (RCC) we carried out a pilot study of vascular properties in a series of archival primary kidney tumours in patients of different ages. PATIENTS AND METHODS: A cohort of patients with RCC was identified restrospectively, with an age range of 35-84 years. Paraffin-embedded, formalin-fixed sections of surgical tumour specimens were stained for endothelial (CD31, von Willebrand factor [vWF]), pericyte (alpha smooth muscle actin [SMA]) and leucocytic (CD45) markers, as well as for proliferative (Ki67) and angiogenic activity (tumour endothelial markers [TEMs], delta-like 4 [Dll4], Dll1, endothelial nitric oxide synthase [eNOS]). Vascular properties were compared between patients above and below 65 years of age.
RESULTS: Microvascular density (MVD) within capillary hot spots was generally higher in patients with non-metastatic clear-cell RCC (ccRCC; n = 21) than in those with metastatic RCC (mRCC; n= 9). Patients with ccRCC who were more than 65 years old showed significantly higher MVD than their younger (< 65 years) counterparts. There were dividing (Ki67-positive) endothelial and mural cells in both small (< 20 µm) capillary and large (> 20 µm), pre-capillary vessels, suggesting the involvement of both angiogenic and remodelling/arteriogenic processes. Tumour endothelial markers (TEM1, TEM7, TEM8), Notch ligands (Dll1, Dll4), and other molecular characteristics (eNOS) were analysed. Age-related differences were observed in the frequency of pre-capillary vessels expressing Dll1, which was significantly higher in tumours of younger patients (< 65 years), while eNOS was more prevalent among capillaries associated with ccRCC in older patients (>6 5 years).
CONCLUSIONS: The results of the present study suggest that age influences the structural and molecular properties of the tumour vasculature in ccRCC. We postulate that vascular ageing could also be relevant in the context of anti-angiogenic therapy.
© 2010 THE AUTHORS. JOURNAL COMPILATION © 2010 BJU INTERNATIONAL.

Entities:  

Mesh:

Year:  2010        PMID: 20804487      PMCID: PMC7447075          DOI: 10.1111/j.1464-410X.2010.09569.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  53 in total

Review 1.  Blood vessels and the aging kidney.

Authors:  David A Long; Wei Mu; Karen L Price; Richard J Johnson
Journal:  Nephron Exp Nephrol       Date:  2005-07-22

2.  Prognostic significance of microscopic vascularity for clear cell renal cell carcinoma.

Authors:  B Delahunt; P B Bethwaite; A Thornton
Journal:  Br J Urol       Date:  1997-09

3.  Evaluation of the prognostic significance of microvessel count and tumor size in renal cell carcinoma.

Authors:  S Yoshino; M Kato; K Okada
Journal:  Int J Urol       Date:  1998-03       Impact factor: 3.369

Review 4.  Tumour vascular targeting.

Authors:  Dario Neri; Roy Bicknell
Journal:  Nat Rev Cancer       Date:  2005-06       Impact factor: 60.716

5.  Aging, progenitor cell exhaustion, and atherosclerosis.

Authors:  Frederick M Rauscher; Pascal J Goldschmidt-Clermont; Bryce H Davis; Tao Wang; David Gregg; Priya Ramaswami; Anne M Pippen; Brian H Annex; Chunming Dong; Doris A Taylor
Journal:  Circulation       Date:  2003-07-14       Impact factor: 29.690

6.  Expression and clinical significance of Notch receptors in human renal cell carcinoma.

Authors:  Shiren Sun; Rui Du; Juan Gao; Xiaoxuan Ning; Huahong Xie; Xia Lin; Jie Liu; Daiming Fan
Journal:  Pathology       Date:  2009       Impact factor: 5.306

7.  Clinical significance of tumor angiogenesis in patients with localized renal cell carcinoma.

Authors:  O Nativ; E Sabo; A Reiss; M Wald; S Madjar; B Moskovitz
Journal:  Urology       Date:  1998-05       Impact factor: 2.649

Review 8.  The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer.

Authors:  William G Kaelin
Journal:  Nat Rev Cancer       Date:  2008-10-16       Impact factor: 60.716

Review 9.  Metastatic renal cell carcinoma: many treatment options, one patient.

Authors:  Brian I Rini
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

Review 10.  Arteriogenesis: role of nitric oxide.

Authors:  B M Prior; P G Lloyd; J Ren; Z Li; H T Yang; M H Laughlin; R L Terjung
Journal:  Endothelium       Date:  2003
View more
  10 in total

Review 1.  Notch in the kidney: development and disease.

Authors:  Yasemin Sirin; Katalin Susztak
Journal:  J Pathol       Date:  2011-08-24       Impact factor: 7.996

2.  Efficacy and safety of sunitinib in elderly patients with advanced renal cell carcinoma.

Authors:  Tetsuo Fujita; Takahiro Hirayama; Daisuke Ishii; Kazumasa Matsumoto; Kazunari Yoshida; Masatsugu Iwamura
Journal:  Mol Clin Oncol       Date:  2018-07-26

3.  Efficacy and safety of axitinib in elderly patients with metastatic renal cell carcinoma.

Authors:  Hideaki Miyake; Ken-Ichi Harada; Seiichiro Ozono; Masato Fujisawa
Journal:  Med Oncol       Date:  2016-07-21       Impact factor: 3.064

Review 4.  Understanding angiogenesis during aging: opportunities for discoveries and new models.

Authors:  Nicholas A Hodges; Ariana D Suarez-Martinez; Walter L Murfee
Journal:  J Appl Physiol (1985)       Date:  2018-04-12

Review 5.  Resistance to metronomic chemotherapy and ways to overcome it.

Authors:  Maria Riesco-Martinez; Karla Parra; Ronak Saluja; Giulio Francia; Urban Emmenegger
Journal:  Cancer Lett       Date:  2017-03-01       Impact factor: 8.679

6.  53 years old is a reasonable cut-off value to define young and old patients in clear cell renal cell carcinoma: a study based on TCGA and SEER database.

Authors:  Fucai Tang; Zechao Lu; Chengwu He; Hanbin Zhang; Weijia Wu; Zhaohui He
Journal:  BMC Cancer       Date:  2021-05-29       Impact factor: 4.430

7.  Clinical outcome of advanced and metastatic renal cell carcinoma treated with targeted therapy: is there a difference between young and old patients?

Authors:  Guiming Zhang; Yao Zhu; Dahai Dong; Weijie Gu; Hailiang Zhang; Lijiang Sun; Dingwei Ye
Journal:  Onco Targets Ther       Date:  2014-11-03       Impact factor: 4.147

8.  Nomograms for Predicting Overall Survival and Cancer-Specific Survival of Patients With Renal Cell Carcinoma and Venous Tumor Thrombus: A Population-Based Study.

Authors:  Lin Yang; Bin Fu
Journal:  Front Surg       Date:  2022-06-08

9.  Expression of follicle-stimulating hormone receptor by the vascular endothelium in tumor metastases.

Authors:  Ahsan Siraj; Virginie Desestret; Martine Antoine; Gaëlle Fromont; Michel Huerre; Marc Sanson; Philippe Camparo; Christophe Pichon; François Planeix; Julie Gonin; Aurelian Radu; Nicolae Ghinea
Journal:  BMC Cancer       Date:  2013-05-20       Impact factor: 4.430

10.  Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma.

Authors:  T E Hutson; R M Bukowski; B I Rini; M E Gore; J M Larkin; R A Figlin; C H Barrios; B Escudier; X Lin; K Fly; B Martell; E Matczak; R J Motzer
Journal:  Br J Cancer       Date:  2014-01-16       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.